GCM
ACAD icon

Glaxis Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Glaxis Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-13,200
Closed -$362K – 34
2013
Q3 		$362K Buy
+13,200
New +$276K 0.73% 37

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glaxis Capital Management's ACAD Position: Q4 2013 in Review

Glaxis Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2013, closing a stake of 13,200 shares — an estimated $362K sold.

Glaxis Capital Management first reported a position in ACAD in Q3 2013 and held it in 1 quarter. The position peaked at $362K in Q3 2013. 155 funds tracked by Wall St. Rank hold ACAD as of Q4 2013.

  • Glaxis Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Glaxis Capital Management sold 13,200 Acadia Pharmaceuticals shares in Q4 2013, an estimated $362K.
  • Glaxis Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Glaxis Capital Management's Acadia Pharmaceuticals position peaked at $362K in Q3 2013.
  • 155 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2013.

Based on Glaxis Capital Management's 13F filing for Q4 2013, filed 5 Feb 2014.